Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginsenoside Rg1 serving as CCL2-CCR2 signaling pathway inhibitor and central anti-inflammatory drug

A technology of CCL2-CCR2 and ginsenoside, which is applied in anti-inflammatory agents, drug combinations, non-central analgesics, etc., can solve the problems of low success rate of drug development for central diseases and nervous system diseases

Inactive Publication Date: 2015-06-10
CHINA PHARM UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The complexity of central nervous system diseases and the limitations of their understanding make the development success rate of neurological disease drugs very low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside Rg1 serving as CCL2-CCR2 signaling pathway inhibitor and central anti-inflammatory drug
  • Application of ginsenoside Rg1 serving as CCL2-CCR2 signaling pathway inhibitor and central anti-inflammatory drug
  • Application of ginsenoside Rg1 serving as CCL2-CCR2 signaling pathway inhibitor and central anti-inflammatory drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1. Ginsenoside Rg1 inhibits CCL2-induced chemotaxis of human mononuclear cells THP-1 and mouse peripheral blood mononuclear cells. The invention uses Transwell cell migration assay to investigate the antagonistic effect of ginsenoside Rg1 on the monocyte chemotaxis process induced by CCL2. Human mononuclear leukemia cells THP-1 and isolated mouse peripheral blood mononuclear cells were used respectively, and the cells were pretreated with different concentrations for 4 hours, and then CCL2 was given for a period of time. Transwell chemotaxis and migration assay followed by formaldehyde fixation, In the crystal violet staining step, observe under a microscope to observe changes in the amount of cell migration. The results showed that CCL2 could significantly increase the migration of THP-1 cells and mouse peripheral blood cells, while ginsenoside Rg1 could weaken this chemotaxis ( figure 2 ).

Embodiment 2

[0025] Example 2. Ginsenoside Rg1 effectively reduces the increase in intracellular calcium ion signal intensity induced by CCL2.

[0026] The intracellular calcium ion concentration is closely related to the activation of intracellular signaling pathways and cell migration. The invention uses a fluorescence method to measure the antagonistic effect of ginsenoside Rg1 on the increase of intracellular calcium ion signal intensity induced by CCL2. Mouse macrophages Raw267 were used to subculture and cultured in 96-well cell culture plates. When the density was 70-80%, different concentrations of Rg1 were added for 4 hours. After washing with PBS, add Fluo-4AM calcium ion fluorescent probe reagent for a period of time, then add mCCL2, and immediately read on a multi-functional microplate reader, the excitation wavelength is 488nm, and the plate reading interval is 10s. The results showed that CCL2 could rapidly increase the intracellular calcium ion signal intensity in a short t...

Embodiment 3

[0027] Example 3. Ginsenoside Rg1 significantly down-regulates the expression of CCL2-CCR2 downstream signaling pathway proteins.

[0028]The CCL2-CCR2 signaling pathway is associated with the activation of the MAPK pathway. In the present invention, Western Blot immunoblotting method is used to determine the change of ginsenoside Rgl on the level of related kinase protein downstream of CCL2-CCR2 signaling pathway. After pre-incubation with different concentrations of ginsenoside Rg1 for 4 hours, CCL2 was added. After a short period of action, the medium was quickly removed to extract the total protein of the cells. After adding the loading buffer, the total protein was separated by SDS-PAGE. Cut off the band of the target protein, transfer the target protein to PVDF membrane, incubate overnight with the antibody of the target protein respectively, wash off the unbound antibody with TSBS, and incubate the secondary antibody conjugated with horseradish peroxide. After washing ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a natural small molecular compound ginsenoside Rg1 serving as a CCL2-CCR2 signaling pathway inhibitor and an application serving as a central anti-inflammatory drug. The ginsenoside Rg1 provided by the invention is safe and effective, can be used as a drug for treating and preventing nervous system diseases related to central inflammation, and can also be used as a health care product and a tool drug for researching a CCL2-CCR2 signaling pathway.

Description

technical field [0001] The invention belongs to the field of natural products, and relates to a new discovery that natural products regulate the chemotaxis of monocytes, and specifically relates to the fact that ginsenoside Rg1 can interfere with the chemotaxis process of monocytes through the CCL2-CCR2 downstream signaling pathway in an inflammatory state to play a role in monocyte chemotaxis. Applications related to modulating inflammatory responses. Background technique [0002] At present, the incidence of central system diseases (such as depression, Alzheimer's disease, Parkinson's disease) is increasing year by year, which is increasingly threatening human life and health. The complexity of central nervous system diseases and the limitations of their understanding make the success rate of drug development for nervous system diseases very low. Studies have shown that the occurrence and development of diseases in the central nervous system are closely related to inflamm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P29/00A61P25/24A61P25/28
Inventor 王广基郝海平马思静郑啸柴营营王琳
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com